F S&P 500
5,242.25 -4.00 (-0.08%) F Dow Jones
39,619.00 -23.00 (-0.06%) F Nasdaq
18,242.25 -12.75 (-0.07%) E-mini Russell 2000 Index Futur
2,067.10 -0.80 (-0.04%) Petróleo
78.02 -0.24 (-0.31%) Oro
2,368.90 -6.10 (-0.26%)
Spruce Biosciences, Inc. (SPRB)
Fuera de horario:
Spruce Biosciences, Inc.
611 Gateway Boulevard
Suite 740
South San Francisco, CA 94080
United States
415 655 4168
https://www.sprucebiosciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael G. Grey | Executive Chairman | 70k | N/D | 1953 |
| Dr. Javier Szwarcberg M.D., M.P.H. | CEO & Director | 951.85k | N/D | 1970 |
| Mr. Samir M. Gharib CPA, M.B.A. | President & CFO | 683.63k | N/D | 1982 |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer | 647.4k | N/D | 1970 |
| Ms. P. J. Ramtin | Senior Vice President of Business Operations | N/D | N/D | N/D |
| Ms. Heidi Petersen M.P.H. | Senior Vice President of Regulatory & Quality | N/D | N/D | N/D |
Descripción
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Spruce Biosciences, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 9; Derechos del accionista: 8; Compensación: 7.
